SEC Company Response from Autolus Therapeutics plc (AUTL) (CIK 0001730463) (AUTL) — Jun 19, 2018
Autolus Therapeutics plc (AUTL) (CIK 0001730463)
Date: June 19, 2018 · CIK: 0001730463 · Accession: 0001193125-18-196933
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-224720
Letter
June 19, 2018
VIA EDGAR
U.S. Securities and Exchange Commission
Division of Corporation Finance
100 F Street, N.E.
Washington, D.C. 20549
Attn: Ms. Mary Beth Breslin
Ms. Irene Paik
Mr. Mark Brunhofer
Ms. Mary Mast
Re: Autolus Therapeutics plc
Registration Statement on Form F-1 (File No. 333-224720) (the “Registration Statement”)
Ladies and Gentleman:
In connection with the above-referenced Registration Statement and pursuant to Rule 461 under the Securities Act of 1933, as amended (the “Act”), we, as representatives of the several underwriters, hereby join in the request of Autolus Therapeutics plc that the effectiveness of the Registration Statement be accelerated so that it will be declared effective at 4:00 p.m. Eastern Time on June 21, 2018, or as soon thereafter as practicable.
Pursuant to Rule 460 of the General Rules and Regulations under the Act, please be advised that we and the other prospective underwriters have distributed approximately 1,292 copies of the preliminary prospectus dated June 8, 2018 (the “Preliminary Prospectus”) between June 8, 2018 and the date hereof to prospective underwriters, dealers, institutional investors and others.
In connection with the Preliminary Prospectus distribution for the above-referenced issue, we hereby confirm that we are, and the other prospective underwriters have confirmed that they are, complying with the 48-hour requirement as promulgated by Rule 15c2-8 under the Securities Exchange Act of 1934, as amended.
[Remainder of page intentionally left blank]
Very truly yours,
GOLDMAN SACHS & CO. LLC
Show Raw Text
CORRESP 1 filename1.htm CORRESP June 19, 2018 VIA EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Attn: Ms. Mary Beth Breslin Ms. Irene Paik Mr. Mark Brunhofer Ms. Mary Mast Re: Autolus Therapeutics plc Registration Statement on Form F-1 (File No. 333-224720) (the “Registration Statement”) Ladies and Gentleman: In connection with the above-referenced Registration Statement and pursuant to Rule 461 under the Securities Act of 1933, as amended (the “Act”), we, as representatives of the several underwriters, hereby join in the request of Autolus Therapeutics plc that the effectiveness of the Registration Statement be accelerated so that it will be declared effective at 4:00 p.m. Eastern Time on June 21, 2018, or as soon thereafter as practicable. Pursuant to Rule 460 of the General Rules and Regulations under the Act, please be advised that we and the other prospective underwriters have distributed approximately 1,292 copies of the preliminary prospectus dated June 8, 2018 (the “Preliminary Prospectus”) between June 8, 2018 and the date hereof to prospective underwriters, dealers, institutional investors and others. In connection with the Preliminary Prospectus distribution for the above-referenced issue, we hereby confirm that we are, and the other prospective underwriters have confirmed that they are, complying with the 48-hour requirement as promulgated by Rule 15c2-8 under the Securities Exchange Act of 1934, as amended. [Remainder of page intentionally left blank] Very truly yours, GOLDMAN SACHS & CO. LLC JEFFERIES LLC As Representatives of the several Underwriters GOLDMAN SACHS & CO. LLC. By: /s/ Elizabeth Wood Name: Elizabeth Wood Title: Managing Director JEFFERIES LLC By: /s/ Matthew Kim Name: Matthew Kim Title: Managing Director [Signature Page to Request for Acceleration of Effectiveness]